Retail and Pharmacy Segments Show Strength Amid Industry Challenges
CVS Health (CVS) beat Wall Street expectations with its fourth-quarter and full-year 2024 earnings, sending its stock up nearly 8% in pre-market trading on Wednesday.
The company reported full-year revenue of $372.8 billion, while Q4 revenue reached $97.7 billion, slightly above analyst estimates of $96.8 billion. Despite ongoing headwinds in its health care benefits segment, particularly in Medicare and Medicaid, strong retail and pharmaceutical sales helped offset the decline.
CVS reported a medical loss ratio (MLR) of 92.5%, a notable improvement from Q3’s record-high 95.2%. MLR measures the percentage of premium dollars spent on claims, with lower values being more favorable for insurers.
Even with a new White House administration, CVS remains exposed to potential regulatory changes that could impact pharmacy benefit managers (PBMs), a key part of its business. As the largest PBM in the U.S., CVS faces ongoing scrutiny over drug pricing and reimbursement models.
The company concluded a turbulent year with David Joyner stepping in as CEO. In 2024, CVS grappled with activist investors, considered breaking up the company, and saw its profit decline by 38% to $8.5 billion, compared to $13.7 billion in 2023. Its stock also fell 40% last year.
For 2025 guidance, CVS projected adjusted EPS between $5.75 and $6, but did not provide a revenue forecast.
“We have continued to see growth in key areas, including Pharmacy and Consumer Wellness, while navigating industry-wide challenges in Health Care Benefits,” Joyner stated.
Investors welcomed the improved financial outlook, driving the stock higher as CVS aims to stabilize and regain investor confidence in 2025.
You might like this article:Lattice Semiconductor Shares Surge After Strong Q1 Outlook
